# BPC-157: Research Overview > BPC-157: Research Overview — whatisapeptide — A literature summary of BPC-157, a 15-amino-acid gastric-protein fragment studied mostly in rodents for tissue repair and angiogenesis. Covers mechanism, findings, reported effects, and cited safety cautions. **01 / RESEARCH PEPTIDE FUNDAMENTALS** A 15-amino-acid fragment of a human gastric-juice protein, studied almost entirely in rodents for tissue repair, angiogenesis, and gut protection — with human evidence still limited to a handful of small pilot studies. ## The short version BPC-157 (short for Body Protection Compound 157) is a synthetic 15-amino-acid peptide copied from part of a protein found in human gastric (stomach) juice. In animal studies it has been linked to faster healing of tendons, ligaments, and stomach-lining injuries, largely by promoting the growth of new blood vessels (angiogenesis). Almost everything known about BPC-157 comes from rats, dogs, and lab cell cultures. As of 2025, only three small human pilot studies exist, and a 2025 review says rigorous, large-scale human trials are still lacking [2]. It is not an approved medicine anywhere, and it's sold only as a research chemical, not for human consumption. Nothing on this page is a recommended dose or a treatment suggestion — it summarizes what has actually been studied, and where the evidence stops. ## What it is BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular formula C62H98N16O22). It's derived from a partial sequence of a human gastric-juice protein called BPC, and it goes by several names in the literature and on supplier labels, including Pentadecapeptide BPC 157, PL 14736, and PLD-116. Its category in the research literature is a 'stable gastric pentadecapeptide' — stable meaning it resists the rapid breakdown that would normally happen to a fragment this size once released into digestive fluid or the bloodstream, at least long enough to produce measurable effects in animal models. ## How it works BPC-157 is described in the literature as a cytoprotective peptide — one that protects and helps repair tissue — and its effects in animal models are most consistently tied to angiogenesis, the growth of new blood vessels. The best-characterized pathway is up-regulation of the VEGFR2 receptor (a receptor tied to vessel growth) along with its internalization into cells, triggering downstream VEGFR2-Akt-eNOS signaling, which increases nitric oxide and supports new vessel formation [4]. Other reported routes include the FAK-paxillin pathway (involved in cell migration), sensitization of the growth-hormone receptor in tendon fibroblasts, the cells that build tendon tissue [6], and effects on the nitric-oxide system and several neurotransmitter systems, including serotonin and dopamine, that researchers link to a proposed 'brain-gut axis' role [7]. ## What the research shows *A first-in-human safety pilot.* In 2025, two healthy adults (a 58-year-old man and a 68-year-old woman) received intravenous BPC-157 up to 20 mg. It was well tolerated, with no adverse events and no measurable changes in cardiac, liver, kidney, thyroid, or glucose biomarkers — though a two-person study cannot establish effectiveness, only that this small dose was tolerated in this tiny sample [1]. *The state of human evidence, honestly.* A 2025 narrative review found only three pilot human studies of BPC-157 in the entire published literature, concluded that rigorous, large-scale trials are lacking, and recommended treating BPC-157 as investigational given the regulatory controversy and unregulated availability of research-chemical products [2]. *Pharmacokinetics — how fast it clears.* The first formal characterization of BPC-157's pharmacokinetics, in rats and beagle dogs, found linear kinetics, an elimination half-life under 30 minutes, and modest bioavailability via intramuscular injection (about 14-19% in rats, 45-51% in dogs), with rapid breakdown into small fragments that enter normal amino-acid metabolism [3]. *The foundational animal findings.* In Wistar rats, BPC-157 reduced gastric ulcer area and sped ulcer healing, with intramuscular delivery working better than intragastric delivery [5]. In a separate rat study, it accelerated healing of a fully transected Achilles tendon across biomechanical, functional, and microscopic measures, and stimulated tendon-cell growth in a lab dish [6]. Vessel-growth studies in chick membranes, ischemic rat hindlimbs, and human endothelial cells found BPC-157 increased vessel density and blood-flow recovery, and that blocking cell uptake blocked the effect [4]. ## Reported effects, cautions & safety The following benefits and side effects are reported by people in research-use communities. They are anecdotal, not clinical evidence, and none of them come with a stated dose. *Reported benefits:* The most common reason people describe trying BPC-157 is faster recovery from tendon, ligament, and joint injuries — tennis elbow, rotator-cuff strain, old sprains — often noticing improvement within one to three weeks. Many also describe less joint stiffness, easier digestion, a general sense of reduced inflammation, faster healing of minor skin wounds, and better sleep or mood. All of these are personal accounts, not results from controlled human trials. *Reported side effects:* The most common complaint is a local injection-site reaction — brief stinging, redness, or a small bump that people say fades within a day. A minority report mild nausea or stomach upset, more often with oral products than injections. Less common reports include first-week fatigue, headache, brief dizziness after injecting, a wave of warmth or flushing, and — rarely — heart palpitations, which several sources describe as a reason to stop and seek medical evaluation. *Cited safety cautions from the literature:* - **The human evidence is extremely thin.** Nearly everything known comes from rodents; only a handful of small human pilots exist, and large controlled trials are lacking [2]. - **Much of the foundational research comes from one research group**, limiting independent replication [2]. - **It is not an approved drug**, and unregulated research-chemical products carry no verified purity or dose [2]. - **Strong pro-angiogenic activity raises a theoretical cancer concern**, since tumors also depend on new blood vessels — this is mechanism-based reasoning, not a human finding [4]. - **A possible interaction with serotonin-affecting medicines** is suggested by rodent data connecting BPC-157 to serotonin activity, though no human interaction study exists [7]. - **It's prohibited in competitive sport** by the World Anti-Doping Agency's non-approved-substances category. ## Where BPC-157 fits in research peptide fundamentals BPC-157 is this site's illustration of a *protein fragment turned research peptide*: a 15-amino-acid slice of a much larger gastric protein, stable enough to survive long enough to act, but with a research record that is overwhelmingly animal-based. Compare that origin story with [GHK-Cu](/ghk-cu) and [KPV](/kpv), both even shorter three-amino-acid fragments, or with [semaglutide](/semaglutide), which starts from a hormone and is deliberately engineered rather than isolated. See the [full comparison](/compare) for how all four stack up. ![BPC-157 research illustration — abstract regenerative motif](/images/bpc-157.webp) --- whatisapeptide.com is an independent reference desk on peptide biology and its supporting literature — not a clinic, a pharmacy, or a source of medical advice.